Oriental Aromatics Ltd
OALOriental Aromatics Ltd's price has outrun its earnings. +58.4% in a year against EPS −90.4% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +58.4% in a year while annual EPS moved −90.4% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (13 weeks in) while the P/E sits at the 99th percentile of its own 8-year range. Underneath, the last four quarters read improving — profit +402.0% year on year, and 239% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Oriental Aromatics Ltd trades at ₹534, in a confirmed uptrend and 13 weeks into that stage. That is +54.1% against its own 200-day average. It sits at 100% of a 52-week range of ₹235 to ₹534. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 3 straight weeks.
Today the stock is in a confirmed uptrend — week 13 of stage 2, confirmed. At ₹534 it trades +54.1% versus its 200-day average and sits at 100% of its 52-week range (₹235–₹534).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +371% while the NIFTY 500 moved +267% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 3 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Oriental Aromatics Ltd trades at 337.0× P/E, about the priciest it has ever traded. Its long-run median P/E is 33.8×, measured across 8.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 337.0× is about the priciest it has ever traded, against a long-run median of 33.8× measured over 8.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −90.4% against a +58.4% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the −10.8%/yr price move, ~−45.9%/yr came from earnings growth and ~+35.1 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Oriental Aromatics Ltd reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −77.7% latest against +25205.9% at its 12-quarter best), ROCE holding at 4.0%. The read is built from 8 quarters across 4 curves, on partial evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +11.1% | +6.5% | +7.8% | — |
| Profit | −91.2% | −46.9% | −50.6% | — |
| EPS | −90.4% | −44.9% | −49.7% | — |
| Share price | +58.4% | +11.3% | −10.8% | +13.0% |
4-Factor Sector Score
36.0/100 — rank 16 of 20 in Chemicals - Organic · 74% evidence confidence
Oriental Aromatics Ltd scores 36.0 out of 100 against the 20 companies it is compared with in Chemicals - Organic, ranking 16. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 12.5 + 4.3 + 8.7 + 10.5 = 36. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Oriental Aromatics Ltd reported ₹260 Cr of revenue in the Jun 26 quarter, +15.2% year on year. That is the 10th straight quarter of year-on-year growth. Over 9 years it has compounded at 9.4% a year. The last full year, FY26, came in at ₹1,031 Cr. The last four reported quarters add to ₹1,065 Cr.
FY26 revenue came in at ₹1,031 Cr (+11.1% on the year), capping 9 years at 9.4% compound. The latest quarter (Jun 26) printed ₹260 Cr, +15.2% year on year — the 10th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +13.6% growth against the decade's 9.4% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +13.5% over the last 4 quarters against +11.5%/yr over the last 8 — stabilising; TTM profit −77.7% vs −54.9%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Oriental Aromatics Ltd's operating margin is 7.6% in the Jun 26 quarter, −0.4 percentage points against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 6.0% to 22.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 7.6%, −0.4 pp against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 6.0%–22.0%.
🚨 Why the margin moved: operating margin went −0.4 pp year on year while gross margin went −5.8 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Oriental Aromatics Ltd earned ₹2.5 Cr of net profit in the Jun 26 quarter, +402.0% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹3.0 Cr. The 9-year compound rate is −22.0%. That is 1.0% of the quarter's revenue. The same quarter a year earlier earned ₹0.5 Cr.
Jun 26 profit was ₹2.5 Cr, +402.0% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹3.0 Cr (−91.2%), and the 9-year compound rate is −22.0%.
Why profit moved: revenue contributed +15.2% and the margin −0.4 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +90.3% vs revenue +13.6%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 239% of Oriental Aromatics Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹2.0 Cr of operating cash against ₹3.0 Cr of profit. After ₹11.0 Cr of capital spending, ₹−9.0 Cr was left as free cash.
FY26: operating cash of ₹2.0 Cr against reported profit of ₹3.0 Cr, leaving free cash of ₹−9.0 Cr after ₹11.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 239% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 239%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 2.9× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Oriental Aromatics Ltd's cash conversion cycle runs 247 days in FY26, up from 242 days in FY21. Capital spending ran ₹214 Cr over the last 3 years. At FY26 sales of ₹1,031 Cr each day of that cycle holds about ₹2.8 Cr, so roughly ₹698 Cr sits inside the business at any moment.
FY26: debtors at 89 days, inventory at 203 days — roughly 6.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 247 days, looser than FY21's 242.
The full loop: cash goes out to suppliers and production on day 0; stock waits 203 days to sell; customers pay about 89 days after that; and suppliers themselves are paid at 44 days — netting out to the 247-day cycle.
In money terms: at FY26 sales of ₹1,031 Cr, each day of the cycle holds about ₹2.8 Cr — so the 247-day loop keeps roughly ₹698 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹214 Cr over the last 3 fiscal years against ₹75.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹5.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Oriental Aromatics Ltd earns a ROCE of 4% in FY26. Return on invested capital clears the cost of that capital by −10.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 0.3% net margin on 0.86× asset turns.
FY26 ROCE is 4%.
🚨 Why the return is what it is — the wiring (FY26): 0.3% net margin × 0.86× asset turns × 1.80× balance-sheet leverage ≈ 0.5% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 1.4% − 12.0% = a −10.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Oriental Aromatics Ltd carries total debt of ₹403 Cr against shareholder equity of ₹665 Cr as of Mar 26, a debt-to-equity of 0.61. On the annual view that ratio went from 0.23 in FY22 to 0.61 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹403 Cr against shareholder equity of ₹665 Cr — a debt-to-equity of 0.61. On the annual view, debt-to-equity went from 0.23 (FY22) to 0.61 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Oriental Aromatics Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved +0.0 points over the same window, to 74.2%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −0.1 points over 8 quarters to 0.0%; Promoters: +0.0 points over 8 quarters to 74.2%; Domestic institutions: +0.0 points over 8 quarters to 0.0%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Oriental Aromatics Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Valiant Organics LtdVALIANTORG | 63.2/100Mixed-positive evidence87% evidence | TURNING | 24.4/35 Revenue 1.5% · PAT 100% · OPM change 6 pp 95% evidence | 10.8/25 ROCE 5.5% · OPM 18% 95% evidence | 11.0/20 P/E 22× · PEG — 50% evidence | 17.0/20 RS sector 9.4% · RS bench 42.8% · 1Y 9.4%5 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 10.8 + 11 + 17 = 63.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Foseco India LtdFOSECOIND | 63.1/100Mixed-positive evidence87% evidence | BREAKING OUT | 19.5/35 Revenue 32.6% · PAT 20.5% · OPM change 5.2 pp 100% evidence | 16.9/25 ROCE 17.4% · OPM 23% 100% evidence | 11.5/20 P/E 44.8× · PEG 1.31 65% evidence | 15.2/20 RS sector 24.1% · RS bench 21% · 1Y -4%6 of 10 weeks ahead 70% evidence |
| Exact sum: 19.5 + 16.9 + 11.5 + 15.2 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Elantas Beck India LtdELANTAS | 62.3/100Mixed-positive evidence76% evidence | BREAKING OUT | 26.3/35 Revenue 17.6% · PAT 33.1% · OPM change 10 pp 95% evidence | 19.1/25 ROCE 21.2% · OPM 29% 76% evidence | 6.3/20 P/E 64.8× · PEG — 50% evidence | 10.6/20 RS sector -6.6% · RS bench 52.4% · 1Y 35.2%6 of 9 weeks ahead 70% evidence |
| Exact sum: 26.3 + 19.1 + 6.3 + 10.6 = 62.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 4OCCL LtdOCCLLTD | 61.4/100Mixed-positive evidence60% evidence | BREAKING OUT | 26.5/35 Revenue 40.6% · PAT 100% · OPM change 7 pp 95% evidence | 12.2/25 ROCE 13% · OPM 28% 76% evidence | 11.5/20 P/E 10.4× · PEG — 15% evidence | 11.2/20 RS sector — · RS bench 41.5% · 1Y —9 of 9 weeks ahead 25% evidence |
| Exact sum: 26.5 + 12.2 + 11.5 + 11.2 = 61.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Shri Ahimsa Naturals LtdSHRIAHIMSA | 61.0/100Thin evidence · provisional56% evidence | LEADER | 18.9/35 Revenue — · PAT — · OPM change -2 pp 26% evidence | 18.0/25 ROCE 21.7% · OPM 28% 95% evidence | 10.0/20 P/E 37.2× · PEG — 15% evidence | 14.1/20 RS sector 22.9% · RS bench 58.3% · 1Y 113%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 18 + 10 + 14.1 = 61 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Indo Amines LtdINDOAMIN | 60.6/100Mixed-positive evidence81% evidence | BASING | 22.3/35 Revenue 13.3% · PAT 24.2% · OPM change 3 pp 95% evidence | 16.8/25 ROCE 19.9% · OPM 14% 95% evidence | 14.0/20 P/E 11.3× · PEG — 50% evidence | 7.5/20 RS sector -11.9% · RS bench 4.6% · 1Y -12.6%4 of 10 weeks ahead 70% evidence |
| Exact sum: 22.3 + 16.8 + 14 + 7.5 = 60.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Balaji Amines LtdBALAMINES | 59.3/100Mixed-positive evidence82% evidence | LEADER | 26.4/35 Revenue 11.1% · PAT 41.6% · OPM change 10 pp 95% evidence | 13.3/25 ROCE 11% · OPM 25% 76% evidence | 7.0/20 P/E 36.1× · PEG — 50% evidence | 12.6/20 RS sector 18.3% · RS bench 51.3% · 1Y 53.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.4 + 13.3 + 7 + 12.6 = 59.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Nitta Gelatin India LtdNITTAGELA | 59.2/100Mixed-positive evidence72% evidence | TURNING | 18.8/35 Revenue 10.5% · PAT 24.1% · OPM change 4 pp 95% evidence | 19.1/25 ROCE 27.7% · OPM 24% 95% evidence | 9.7/20 P/E 14.4× · PEG — 50% evidence | 11.6/20 RS sector — · RS bench 46.7% · 1Y —7 of 9 weeks ahead 25% evidence |
| Exact sum: 18.8 + 19.1 + 9.7 + 11.6 = 59.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9BASF India LtdBASF | 52.7/100Mixed-positive evidence94% evidence | BREAKING OUT | 20.0/35 Revenue 6.5% · PAT 62.4% · OPM change 4 pp 100% evidence | 10.7/25 ROCE 14.5% · OPM 10% 100% evidence | 14.3/20 P/E 25.7× · PEG 1.62 100% evidence | 7.7/20 RS sector -3.3% · RS bench -3.4% · 1Y -21.2%4 of 11 weeks ahead 70% evidence |
| Exact sum: 20 + 10.7 + 14.3 + 7.7 = 52.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10GFL LtdGFLLIMITED | 51.5/100Mixed-positive evidence72% evidence | BREAKING OUT | 23.9/35 Revenue 10.5% · PAT 100% · OPM change 1064 pp 71% evidence | 7.8/25 ROCE 2.1% · OPM 28.2% 95% evidence | 11.3/20 P/E 10.6× · PEG — 15% evidence | 8.5/20 RS sector -14% · RS bench 12.9% · 1Y -2.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 23.9 + 7.8 + 11.3 + 8.5 = 51.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Laxmi Organic Industries LtdLXCHEM | 49.5/100Mixed-negative evidence94% evidence | BREAKING OUT | 19.9/35 Revenue 5.5% · PAT 26% · OPM change 7.6 pp 100% evidence | 8.4/25 ROCE 4.7% · OPM 12% 100% evidence | 14.7/20 P/E 38.8× · PEG 1.14 100% evidence | 6.5/20 RS sector -19.5% · RS bench 9.7% · 1Y -16.6%9 of 10 weeks ahead 70% evidence |
| Exact sum: 19.9 + 8.4 + 14.7 + 6.5 = 49.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Fine Organic Industries LtdFINEORG | 45.6/100Mixed-negative evidence100% evidence | BREAKING OUT | 14.8/35 Revenue 7.1% · PAT 5.8% · OPM change 4 pp 100% evidence | 17.6/25 ROCE 21.5% · OPM 25% 100% evidence | 7.2/20 P/E 36.2× · PEG 2.7 100% evidence | 6.0/20 RS sector -13.8% · RS bench 12.9% · 1Y 7.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 14.8 + 17.6 + 7.2 + 6 = 45.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Jyoti Resins and Adhesives LtdJYOTIRES | 43.1/100Mixed-negative evidence69% evidence | 9.7/35 Revenue 12.8% · PAT -11.1% · OPM change -13 pp 95% evidence | 19.2/25 ROCE 36.5% · OPM 14% 76% evidence | 10.8/20 P/E 16.2× · PEG — 15% evidence | 3.4/20 RS sector -19.8% · RS bench -11.8% · 1Y -31.4%0 of 12 weeks ahead 70% evidence | |
| Exact sum: 9.7 + 19.2 + 10.8 + 3.4 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Sigachi Industries LtdSIGACHI | 41.5/100Mixed-negative evidence79% evidence | BREAKING OUT | 9.0/35 Revenue -9.6% · PAT 100% · OPM change -5.2 pp 71% evidence | 7.2/25 ROCE 6.2% · OPM 13.6% 95% evidence | 8.4/20 P/E 64.5× · PEG — 50% evidence | 16.9/20 RS sector 6.2% · RS bench 38.7% · 1Y 20.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 9 + 7.2 + 8.4 + 16.9 = 41.5 · Decision use: Price leads the evidence: RS versus the benchmark is 38.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 15Shree Ganesh Remedies LtdSGRL | 41.1/100Mixed-negative evidence76% evidence | 6.6/35 Revenue -8.8% · PAT -29.4% · OPM change -6.3 pp 95% evidence | 14.6/25 ROCE 14.1% · OPM 23.3% 76% evidence | 7.1/20 P/E 54.8× · PEG — 50% evidence | 12.8/20 RS sector 3.3% · RS bench 25.3% · 1Y 15.5%4 of 12 weeks ahead 70% evidence | |
| Exact sum: 6.6 + 14.6 + 7.1 + 12.8 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Oriental Aromatics Ltdthis pageOAL | 36.0/100Mixed-negative evidence74% evidence | BREAKING OUT | 12.5/35 Revenue 13.5% · PAT -77.7% · OPM change -0.4 pp 95% evidence | 4.3/25 ROCE 4.5% · OPM 7.6% 95% evidence | 8.7/20 P/E 337× · PEG — 15% evidence | 10.5/20 RS sector -8.7% · RS bench 66.9% · 1Y 57.7%10 of 10 weeks ahead 70% evidence |
| Exact sum: 12.5 + 4.3 + 8.7 + 10.5 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Fairchem Organics LtdFAIRCHEMOR | 33.6/100Adverse evidence87% evidence | BREAKING OUT | 17.1/35 Revenue 0% · PAT 50% · OPM change 6 pp 95% evidence | 6.0/25 ROCE 3.3% · OPM 10% 95% evidence | 8.0/20 P/E 52× · PEG — 50% evidence | 2.5/20 RS sector -26.6% · RS bench -3.9% · 1Y -22.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 6 + 8 + 2.5 = 33.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Gem Aromatics LtdGEMAROMA | 24.4/100Adverse evidence65% evidence | ASLEEP | 1.8/35 Revenue -24.3% · PAT -80% · OPM change -13.6 pp 95% evidence | 6.4/25 ROCE 3.4% · OPM 3.3% 95% evidence | 8.5/20 P/E 772.2× · PEG — 15% evidence | 7.7/20 RS sector — · RS bench -10.4% · 1Y -39.3%5 of 10 weeks ahead 25% evidence |
| Exact sum: 1.8 + 6.4 + 8.5 + 7.7 = 24.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Sacheerome LtdSACHEEROME | 59.1/100Thin evidence · provisional41% evidence | BREAKING OUT | 17.3/35 Revenue — · PAT — · OPM change 1 pp 26% evidence | 20.3/25 ROCE 35.7% · OPM 23% 95% evidence | 9.7/20 P/E 40.1× · PEG — 15% evidence | 11.8/20 RS sector — · RS bench 46.9% · 1Y 155.5%9 of 10 weeks ahead 25% evidence |
| Exact sum: 17.3 + 20.3 + 9.7 + 11.8 = 59.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Citurgia Biochemicals LtdCITURGIA | 36.7/100Thin evidence · provisional27% evidence | 11.8/35 Revenue — · PAT -68.2% · OPM change — 33% evidence | 4.9/25 ROCE -2150% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 11.8 + 4.9 + 10 + 10 = 36.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Oriental Aromatics Ltd's share price today?
Oriental Aromatics Ltd trades at ₹534, +58.4% over the past year. The company is valued at ₹1,791 Cr. The stock sits at the very top of its 52-week range (₹235–₹534), +54.1% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 13 weeks in. — as of 11 September 2026.
What were Oriental Aromatics Ltd's latest quarterly results?
Oriental Aromatics Ltd reported revenue of ₹260 Cr and net profit of ₹2.5 Cr for the Jun 26 quarter. Revenue rose 15.2% and profit rose 402.0% year on year. Earnings per share were ₹0.75. The operating margin was 7.6%, 0.4 pp lower than a year earlier. — as of 11 September 2026.
What is Oriental Aromatics Ltd's revenue?
Oriental Aromatics Ltd reported revenue of ₹260 Cr in the Jun 26 quarter, +15.2% year on year. For the full FY26 fiscal year, revenue was ₹1,031 Cr (+11.1%). Over the last 9 years revenue compounded at 9.4% a year. — as of 11 September 2026.
What is Oriental Aromatics Ltd's profit?
Oriental Aromatics Ltd earned ₹2.5 Cr of net profit in the Jun 26 quarter, +402.0% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹3.0 Cr. The operating margin ran 7.6% in the latest quarter. — as of 11 September 2026.
What is Oriental Aromatics Ltd's market cap?
Oriental Aromatics Ltd's market capitalisation is ₹1,791 Cr at a share price of ₹534. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Oriental Aromatics Ltd's P/E ratio?
Oriental Aromatics Ltd trades at a P/E of 337.0×, at the 99th percentile of its own 8-year range, against a long-run median of 33.8×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Oriental Aromatics Ltd pay a dividend?
Yes — Oriental Aromatics Ltd's dividend payout was 51% of profit in FY26, and it recorded a payout in each of its last 10 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Oriental Aromatics Ltd overvalued?
On its own history, Oriental Aromatics Ltd looks expensive: its P/E of 337.0× sits at the 99th percentile of its 8-year range (long-run median 33.8×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Oriental Aromatics Ltd growing?
Yes — Oriental Aromatics Ltd is growing: latest-quarter revenue +15.2% year on year, profit +402.0%, and the margin −0.4 pp at 7.6%. The 9-year compound rates are 9.4% (revenue) and −22.0% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Oriental Aromatics Ltd performing?
Oriental Aromatics Ltd is in a confirmed uptrend, 13 weeks in. Its latest quarter's revenue rose 15.2% and profit rose 402.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Oriental Aromatics Ltd in?
Deteriorating — profit and EPS growth are shrinking (profit growth −77.7% latest against +25205.9% at its 12-quarter best), ROCE holding at 4.0%. The read comes from the last 12 quarters of growth (revenue growth +13.5% latest, profit growth −77.7% latest, eps growth −77.5% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Oriental Aromatics Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 13 of stage 2), trading +54.1% versus its 200-day average and at the very top of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Oriental Aromatics Ltd beating the market?
On recent form, yes — Oriental Aromatics Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 3 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +371% against the NIFTY 500's +267% — ahead of the index over the full window. — as of 11 September 2026.
Will Oriental Aromatics Ltd's share price go up?
This page publishes no price forecast for Oriental Aromatics Ltd. What it measures instead: the share price is ₹534, the price is in a confirmed uptrend 13 weeks in. Its P/E of 337.0× sits at the 99th percentile of its own 8-year range. — as of 11 September 2026.
Who owns Oriental Aromatics Ltd?
Promoters hold 74.2% of Oriental Aromatics Ltd, foreign institutions 0.0%, domestic institutions 0.0% and the public 25.8% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.
Does Oriental Aromatics Ltd have too much debt?
It is moderate — Oriental Aromatics Ltd's debt-to-equity is 0.61, and operating profit covers the interest bill 2×. FY26 borrowings were ₹403 Cr against equity of ₹665 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.
What is Oriental Aromatics Ltd's capex?
Oriental Aromatics Ltd spent ₹214 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹11.0 Cr, with ₹5.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Oriental Aromatics Ltd's cash flow?
Oriental Aromatics Ltd generated ₹2.0 Cr of operating cash flow in FY26 and ₹−9.0 Cr of free cash flow after ₹11.0 Cr of capital spending. Reported profit that year was ₹3.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Oriental Aromatics Ltd's profit real cash?
Yes — over the last 3 fiscal years, 239% of Oriental Aromatics Ltd's reported profit arrived as operating cash. Though the latest year ran at 67% — the trend is the thing to watch. In FY26, operating cash was ₹2.0 Cr against reported profit of ₹3.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Oriental Aromatics Ltd in its business cycle?
Oriental Aromatics Ltd's FY26 operating margin was 7.0%, against a 10-year band of 6.0%–22.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 7.6%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Oriental Aromatics Ltd story?
The sharpest disagreement: the price moved +58.4% in a year while annual EPS moved −90.4% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Oriental Aromatics Ltd a stock worth studying right now?
This is not investment advice. The machine read: Oriental Aromatics Ltd's price has outrun its earnings. +58.4% in a year against EPS −90.4% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!